Healthcare

Global Healthcare Weekly

In our global healthcare weekly, we focus on key stock catalysts for biotech companies before April 2025. NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medications aimed at reducing the risk of cardiovascular A critical upcoming catalyst for NewAmsterdam is the topline data from its pivotal Phase 3 TANDEM trial, evaluating the fixed-dose combination (FDC) of obicetrapib and ezetimibe in adult patient Gyre Therapeutics Inc. (NASDAQ: GYRE) is a biopharmaceutical company focused on research and clinical development of protease therapeutics to address unmet medical needs in disorders of the comp A pivotal catalyst for Gyre Therapeutics is the topline data readout anticipated in early 2025 from its Phase 3 clinical trial evaluating hydronidone for chronic hepatitis B (CHB)-associated liv Immuron Limited (NASDAQ: IMRN) is a biopharmaceutical company focused on developing and commercializing polyclonal antibodies to address unmet medical needs, with research and development activi A key upcoming catalyst for Immuron is the topline data readout expected in April 2025 for its Phase 2 clinical study of Travelan. The study, which aims to evaluate the efficacy of Travelan in p

Biotech Stock Updates

We focus to look at recent key drivers of biotech stocks' price movement. Relmada Therapeutics (NASDAQ: RLMD) reported Phase 2 results for NDV-01 in non-muscle invasive bladder cancer, with a 90% overall response rate, 89% high-grade recurrence-free survival in papillary disease, and 100% complete r Silo Pharma (NASDAQ: SILO) filed a U.S. patent application for SPC-14, an intranasal Alzheimer’s treatment licensed from Columbia University, covering its novel dual targeting of NMDAR and 5-HT4 receptors to address cognitive Senti Biosciences (NASDAQ: SNTI) reported Phase 1 data for SENTI-202 in relapsed/refractory hematologic malignancies, with a 71% overall response rate across evaluable patients, including complete remissions and MRD negativity UroGen Pharma (NASDAQ: URGN) presented new patient-reported outcomes at AUA2025 showing that UGN-102 maintained bladder function, symptom burden, and quality of life in low-grade intermediate-risk NMIBC patients, reinforcing i Portage Biotech (NASDAQ: PRTG) reported preclinical data showing PORT-7, a selective A2B receptor inhibitor, outperformed anti-PD1 therapy in a mesothelioma model, with combination treatment further enhancing efficacy and prom CG Oncology (NASDAQ: CGON) presented Phase 3 BOND-003 Cohort C data at AUA2025 showing cretostimogene grenadenorepvec achieved a 75.5% complete response rate in high-risk BCG-unresponsive NMIBC, with durable responses lasting ADMA Biologics (NASDAQ: ADMA) announced FDA approval of its yield enhancement process, which increases production yields by approximately 20% from the same starting plasma volume, improving manufacturing efficiency. Tharimmune (NASDAQ: THAR) announced FDA feedback indicating no additional clinical trials are needed before submitting a 505(b)(2) NDA for TH104, a buccal film formulation of nalmefene designed for rapid absorption and potenti

V小姐

4 months ago

Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 14 May 2025. Incannex Healthcare (NASDAQ: IXHL) shares closed up 866% at US$0.82 following the completion of patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study evaluating IHL-42X for obstructive sleep apnea (OSA). Bluebird Bio (NASDAQ: BLUE), Carlyle, and SK Capital amended their acquisition agreement. Bluebird stockholders can now choose between US$3.00 per share plus a US$6.84 CVR upon achieving a sales milestone, or US$5.00 p Aytu BioPharma (NASDAQ: AYTU) reported quarterly earnings of US$0.21 per share, exceeding analyst estimates losses of US$0.17 by 223.5% and marking a 140.4% improvement from last year’s US$0.52 loss. Quarterly sales re Septerna (NASDAQ: SEPN) and Novo Nordisk (NASDAQ: NVO) have entered an exclusive global collaboration to discover, develop, and commercialize oral small-molecule medicines for obesity, type 2 diabetes, and other cardio Plus Therapeutics (NASDAQ: PSTV) is expected to report increased earnings on higher revenue for the quarter ending March 2025. Consensus estimates project a US$0.17 per share loss and US$1.85m in revenue. Surpassing th Quoin Pharmaceuticals (NASDAQ: QNRX) observed clear skin improvement in a pediatric peeling skin syndrome study after 12 weeks. Key endpoints showed significant improvement, and the treatment QRX003 was well-tolerated. Allurion Technologies (NASDAQ: ALUR) shares closed up 26% at US$3 following obesity data. Studies highlighted weight loss and muscle gain with their balloon and AI-powered care, both with and without GLP-1s. Combining